Drug Diverter Sentenced to 70 Months in Prison - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Drug Diverter Sentenced to 70 Months in Prison


ePT--the Electronic Newsletter of Pharmaceutical Technology

Arnesto Segredo of Miami, Florida, was sentenced on February 18, 2010, to 70 months in prison for conspiring to divert prescription drugs, according to a press release from US Attorney’s Office. Segredo was convicted in August 2009 of diverting drugs and diverting drugs in interstate commerce.

According to prosecutors, from 2000 through 2002, Segredo had unlicensed wholesale suppliers regularly ship him boxes of the human growth hormones Serostim and Nutropin AQ. Segredo operated the Miami-based prescription-drug wholesaler Life Extension Institute, from 2000-2001, which was not licensed to distribute prescription drugs in the state of Florida. He later ran another Miami drug-wholesaler company, Genendo Purchasing Organization, that was licensed in Florida in 2001.

Serostim is an FDA-approved injectable drug used for the treatment of AIDS-wasting syndrome, and Nutropin AQ is FDA-approved for treatment of growth hormone deficiency. According to a press release from the US Attorney’s Office, evidence showed that the counterfeit Nutropin AQ distributed by Segredo entered the drug-supply chain and caused bodily harm to a child that received the drug.

The Prescription Drug Marketing Act prevents prescription drug diversion and the distribution of counterfeit, stolen, or substandard drugs and requires that wholesalers be licensed by state authorities.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here